Lifyorli (copackaged) is a drug owned by Corcept Therapeutics Inc. It is protected by 10 US drug patents filed in 2026 out of which none have expired yet. Lifyorli (Copackaged)'s patents will be open to challenges from 25 March, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 22, 2041. Details of Lifyorli (copackaged)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8859774 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(7 years from now) | Active |
| US11576907 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(7 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12152028 | Methods Of Preparing Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
Dec, 2041
(15 years from now) | Active |
| US12589094 | NA |
May, 2041
(15 years from now) | Active |
| US11285145 | Concomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And Paclitaxel, A Dual Substrate Of Cyp2C8 And Cyp3A4 |
May, 2041
(15 years from now) | Active |
| US11464764 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Apr, 2040
(13 years from now) | Active |
| US11925626 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Dec, 2039
(13 years from now) | Active |
| US12514849 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound |
Dec, 2039
(13 years from now) | Active |
| US10456392 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(7 years from now) | Active |
| US9273047 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators |
May, 2033
(7 years from now) | Active |
FDA has granted several exclusivities to Lifyorli (copackaged). Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Lifyorli (copackaged), regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Lifyorli (copackaged).
Exclusivity Information
Lifyorli (copackaged) holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Lifyorli (copackaged)'s exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Lifyorli (copackaged) is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Lifyorli (copackaged)'s family patents as well as insights into
ongoing legal events
on those patents.
Lifyorli (copackaged)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lifyorli (copackaged)'s generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 22, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lifyorli (copackaged) Generics:
There are no approved generic versions for Lifyorli (copackaged) as of now.
About Lifyorli (copackaged)
Lifyorli (Copackaged) is a drug owned by Corcept Therapeutics Inc. Lifyorli (Copackaged) uses Relacorilant as an active ingredient. Lifyorli (Copackaged) was launched by Corcept in 2026.
Approval Date:
Lifyorli (copackaged) was approved by FDA for market use on 25 March, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Lifyorli (copackaged) is 25 March, 2026, its NCE-1 date is estimated to be 25 March, 2030.
Active Ingredient:
Lifyorli (copackaged) uses Relacorilant as the active ingredient. Check out other Drugs and Companies using Relacorilant ingredient
Dosage:
Lifyorli (copackaged) is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG;25MG | CAPSULE | Prescription | ORAL |